Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

In Vivo Correlation of Glucose Metabolism, Cell Density and Microcirculatory Parameters in Patients with Head and Neck Cancer: Initial Results Using Simultaneous PET/MRI

  • Matthias Gawlitza ,

    Contributed equally to this work with: Matthias Gawlitza, Sandra Purz

    matthias.gawlitza@medizin.uni-leipzig.de

    Affiliation Department of Diagnostic and Interventional Radiology, University Hospital of Leipzig, Liebigstraße 20, 04103 Leipzig, Germany

  • Sandra Purz ,

    Contributed equally to this work with: Matthias Gawlitza, Sandra Purz

    Affiliation Department of Nuclear Medicine, University Hospital of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany

  • Klaus Kubiessa,

    Affiliation Department of Diagnostic and Interventional Radiology, University Hospital of Leipzig, Liebigstraße 20, 04103 Leipzig, Germany

  • Andreas Boehm,

    Affiliation ENT-Department, University Hospital of Leipzig, Liebigstraße 10–14, 04103 Leipzig, Germany

  • Henryk Barthel,

    Affiliation Department of Nuclear Medicine, University Hospital of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany

  • Regine Kluge,

    Affiliation Department of Nuclear Medicine, University Hospital of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany

  • Thomas Kahn,

    Affiliation Department of Diagnostic and Interventional Radiology, University Hospital of Leipzig, Liebigstraße 20, 04103 Leipzig, Germany

  • Osama Sabri,

    Affiliation Department of Nuclear Medicine, University Hospital of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany

  • Patrick Stumpp

    Affiliation Department of Diagnostic and Interventional Radiology, University Hospital of Leipzig, Liebigstraße 20, 04103 Leipzig, Germany

In Vivo Correlation of Glucose Metabolism, Cell Density and Microcirculatory Parameters in Patients with Head and Neck Cancer: Initial Results Using Simultaneous PET/MRI

  • Matthias Gawlitza, 
  • Sandra Purz, 
  • Klaus Kubiessa, 
  • Andreas Boehm, 
  • Henryk Barthel, 
  • Regine Kluge, 
  • Thomas Kahn, 
  • Osama Sabri, 
  • Patrick Stumpp
PLOS
x

Abstract

Objective

To demonstrate the feasibility of simultaneous acquisition of 18F-FDG-PET, diffusion-weighted imaging (DWI) and T1-weighted dynamic contrast-enhanced MRI (T1w-DCE) in an integrated simultaneous PET/MRI in patients with head and neck squamous cell cancer (HNSCC) and to investigate possible correlations between these parameters.

Methods

17 patients that had given informed consent (15 male, 2 female) with biopsy-proven HNSCC underwent simultaneous 18F-FDG-PET/MRI including DWI and T1w-DCE. SUVmax, SUVmean, ADCmean, ADCmin and Ktrans, kep and ve were measured for each tumour and correlated using Spearman’s ρ.

Results

Significant correlations were observed between SUVmean and Ktrans (ρ = 0.43; p ≤ 0.05); SUVmean and kep (ρ = 0.44; p ≤ 0.05); Ktrans and kep (ρ = 0.53; p ≤ 0.05); and between kep and ve (ρ = -0.74; p ≤ 0.01). There was a trend towards statistical significance when correlating SUVmax and ADCmin (ρ = -0.35; p = 0.08); SUVmax and Ktrans (ρ = 0.37; p = 0.07); SUVmax and kep (ρ = 0.39; p = 0.06); and ADCmean and ve (ρ = 0.4; p = 0.06).

Conclusion

Simultaneous 18F-FDG-PET/MRI including DWI and T1w-DCE in patients with HNSCC is feasible and allows depiction of complex interactions between glucose metabolism, microcirculatory parameters and cellular density.

Introduction

18Fluor-fluorodesoxyglucose positron emission tomography combined with magnetic resonance imaging (18F-FDG-PET/MRI) seems to be a promising modality for imaging of head and neck squamous cell carcinoma (HNSCC). In this type of malignancy an accurate diagnosis of infiltration of surrounding structures is important for local staging and for surgical and radiotherapy planning [14]. With the high soft-tissue contrast of MRI and the superior ability of 18F-FDG-PET to detect vital tumor tissue prior to morphological changes, the advent of combined PET/MRI will open new perspectives in non-invasive imaging [3]. The combination of PET with MRI also opens up options to acquire multimodal molecular imaging parameters simultaneously. This may contribute to a more detailed characterization of molecular processes in vivo [5]. We report about the first study in which glucose metabolism (assessed by 18F-FDG-PET), tumor cellularity (measured by diffusion-weighted imaging, DWI) and microcirculatory parameters (estimated by T1-weighted dynamic contrast-enhanced MRI, T1w-DCE) were simultaneously acquired in patients with HNSCC. Not only are these parameters known to be correlated with molecular markers for angiogenesis, proliferation or cell density [68]; first and foremost they are of special interest for prediction of patient outcome and response to chemotherapy or combined radiochemotherapy. For the future, the combination of these parameters may further facilitate treatment planning and prognostic stratification [912].

Materials and Methods

Patients

From October 2011 to September 2013, 82 consecutive patients with suspected malignancy of the head and neck or a cancer of unknown primary with cervical lymphadenopathy were scheduled to undergo 18F-FDG-PET computed-tomography (18F-FDG-PET/CT) for staging and treatment planning and, without additional radiopharmaceutical administration, an integrated simultaneous PET/MRI study. This study was IRB-approved and all patients gave their written informed consent. Patients were retrospectively included in the current study if they fulfilled the following inclusion criteria: (a) if a de-novo or recurring HNSCC of the upper aerodigestive tract was histopathologically proven either by biopsy or by resection after imaging, (b) if a histopathological report was available for a specimen taken from the area that was suspicious for tumor in imaging, (c) if a dedicated simultaneous PET/MRI of the neck including T1w-DCE and DWI sequences was performed with sufficient image quality not distorted by motion artefacts; (d) if a tumor was delineable in the imaging studies and (e) if there was no ongoing (radio)chemotherapy. Altogether, 17 patients fulfilled all inclusion criteria (see Fig 1).

Imaging preparation

All 17 patients underwent an 18F-FDG-PET/CT protocol on a Siemens Biograph 16 PET/CT scanner and a simultaneous whole-body PET/MR after a fasting period of at least 6 hours. In 15 of 17 patients PET/CT was performed first and then PET/MRI, in two patients PET/MRI was performed prior to PET/CT due to logistic reasons. Administration of 18F-FDG was performed once for both studies, depending on body weight (5 MBq/kg, range 205–396 MBq). Postinjection median uptake time was 83 minutes (range 60–120 minutes) for the first imaging study and 196 minutes (range 150–260 minutes) for the second imaging study.

PET/MRI scanner

All examinations were performed on a simultaneous PET/MRI scanner (Siemens Biograph mMR; Siemens Healthcare, Erlangen, Germany). The system is composed of a PET detector ring mounted into a 3.0T whole-body magnetic resonance tomograph, resulting in a hybrid imager with a bore diameter of 60 cm and a magnet length of 163 cm. Maximum gradient strength accounts for 45 mT/m, slew rate for 200 T/m/s in all three spatial directions. The MRI-compatible PET detector ring is implemented inside the bore and consists of 56 LSO-APD (lutetium oxyorthosilicate scintillation crystals combined with avalanche photodiodes) block detectors with 64 detector ring elements arranged on the z-axis. This yields an axial field of view (FOV) of about 60 cm and a FOV of about 26 cm in z-direction. Maximum scan length is about 160 cm without repositioning. More detailed descriptions of the technical aspects were described in previous publications [13,14].

Simultaneous PET/MRI imaging protocol

Patients were placed in supine position with their arms beside the trunk. PET/MRI was conducted in two steps. First, whole-body imaging without contrast medium was performed in six bed positions (head, neck, thorax, abdomen, pelvis and proximal thighs) with a coronal 3D-encoded gradient-echo sequence for attenuation correction (Dixon-VIBE) followed by coronal T2-weighted turbo inversion recovery magnitude (TIRM) and axial T2-weighted half Fourier single shot turbo spin echo (HASTE) sequences as well as axial echoplanar imaging diffusion weighted images (EPI-DWI) with b-values of 0 and 800. Simultaneous to MRI, PET image acquisition was conducted with 5 minutes of scan time per bed position.

Afterwards, a dedicated PET/MRI of the neck using a combined head and neck coil was performed, which also included a coronal Dixon-VIBE sequence for attenuation correction. This was followed by axial T1-weighted turbo spin echo (TSE) and T2-weighted TSE sequences with fat suppression, a coronal T2-weighted TIRM and an axial DWI-EPI sequence with b-values of 0 and 800 (TR/TE 8620/73 ms, slice thickness 4 mm, voxel size 3.2 x 2.6 x 4.0 mm³). Dynamic contrast-enhanced imaging was performed during the administration of 0.1 mmol Gadobutrol per kg of bodyweight (Gadovist, Bayer Healthcare, Leverkusen, Germany) at a rate of 3 ml per second and flushing with 10 ml of normal saline using a power injector (Spectris Solaris, Medrad/Bayer Healthcare, Leverkusen, Germany). T1w-DCE consisted of 40 subsequent scans with a duration of 6 seconds (40 slices per scan), a TR/TE of 2.47/0.97 ms, a slice thickness of 5 mm, a flip angle of 8° and a voxel size of 1.2 x 1.0 x 5.0 mm³; the contrast application was started after the fifth scan. Furthermore axial and coronal fat saturated T1-weighted TSE sequences and an axial contrast enhanced T1-weighted VIBE sequence were conducted after contrast application. Altogether, the dedicated neck protocol accounts for about 30 min of scan time, during which dedicated PET of the neck was conducted for 10 minutes. PET images were reconstructed using the iterative ordered subset expectation maximization algorithm with 3 iterations and 21 subsets, a Gaussian filter with 3 mm full width at half maximum (FWHM), and a 256 x 256 image matrix. Attenuation correction of the PET data was performed using a four-tissue (fat, soft tissue, air, background) model attenuation map which was generated from a Dixon-Vibe MR sequence. A dedicated description of a typical imaging protocol including the complete set of sequence parameters was published recently [1].

Image analysis

PET data sets were reviewed on a commercially available workstation (using Syngo.Via, Siemens Healthcare, Erlangen, Germany) by one resident in diagnostic radiology with 4 years and one board certified nuclear medicine physician with 7 years of experience in head and neck CT, MR and PET/CT imaging. For all tumors, mean and maximum standardized uptake values (SUV) were analyzed in the PET dataset of the neck with the nuclear medicine physician plotting an isocontour volume of interest (VOI) around the tumor (SUVmax threshold 40%).

T1w-DCE images were processed with a commercially available software module for tissue perfusion estimation (Tissue 4D, Siemens Medical Systems, Erlangen, Germany) as described previously [15]. The software offers a population based approach for the arterial input function (AIF) and the best of three available AIF-options was chosen according to the result of the chi2-parameter, which serves as an error measure for the model fit. After scaling the AIF in relation to the gadolinium dose and modelling it by the most widely used bi-exponential model by Tofts and Kermode [16], the pharmacokinetic parameters Ktrans, kep and ve were calculated. In this two-compartment model, the volume transfer constant Ktrans estimates the diffusion of contrast medium from the plasma through the vessel wall into the interstitial space, thus representing vessel permeability. ve expresses the volume of the extravascular extracellular leakage space (EES). kep is a parameter for diffusion of contrast medium from the EES back to the plasma. It is in close relation with Ktrans and ve and is calculated by the formula kep = Ktrans x ve-1. The basic concept of these parameters and their application in patients with HNSCC is described in greater detail in other publications [15,17]. For each patient, these four parameter maps were projected onto the T2-weighted fat-suppressed TSE sequences and the radiologist delineated the tumor manually on each slice, resulting in mean values of Ktrans, kep and ve averaged over the complete tumor. Attention was paid not to include areas of gross necrosis or large feeding vessels in close proximity into the ROI.

DWI images were transferred to a desktop computer with Mac OS X (Apple, Cupertino, California, USA) and an open-source freeware 4D DICOM viewer (OsiriX, Pixmeo, Geneva Switzerland) [18]. ROI’s were manually drawn on the apparent diffusion coefficient (ADC) maps along the contours of the tumor on each slice in cognitive fusion with the complete MRI and PET datasets; mean and minimal ADC values (ADCmean and ADCmin) were then averaged for the whole tumor volume. Again, necrotic tumor areas were not to be included into the ROI. An example of the combined molecular parameter maps is depicted in Fig 2.

thumbnail
Fig 2. Example of a 59-year old male patient depicting the different molecular parameters obtained by simultaneous PET/MRI.

Note the biopsy-proven secondary squamous cell carcinoma of the base of the tongue on the right side. 23 months ago the patient was operated on a squamous cell carcinoma of the soft palate on the same side.

https://doi.org/10.1371/journal.pone.0134749.g002

Statistical analysis

Statistical analysis and graphics creation was performed with SPSS 20 (IBM SPSS Statistics, Armonk, New York, USA). Values are presented as mean ± standard deviation (SD). Mean value comparison was carried out using the Mann-Whitney-U test. Spearman’s non-parametric rank sum correlation coefficients were calculated between DCE parameters, SUVmax, SUVmean, ADCmean and ADCmin. Significance level was set at p ≤ 0.05.

Results

Of the 17 patients, 15 were male and 2 female. Mean age was 57.7 ± 7.3 years (range 49–79 years). Tumors were 11 primary cancers and 6 recurrent cancers, located in the oral cavity (n = 4), in the oropharynx (n = 8) or in the hypopharynx and larynx (n = 5). In patients with recurrent HNSCC, mean time from the end of therapy to diagnosis of the recurring carcinoma was 46 months (range from 12 to 120 months). Patient and tumor characteristics are shown in Table 1, functional imaging parameters of our patient group are depicted in Table 2.

Significant correlations were observed between SUVmean and Ktrans, and between SUVmean and kep. Significant correlations were also present between the microcirculatory parameters Ktrans and kep, and between kep and ve. Furthermore we noted a trend towards an inverse correlation between SUVmax and ADCmin and a trend and towards a positive correlation between SUVmax and the DCE parameters Ktrans and kep. Also between ADCmean and ve a trend towards a positive correlation was apparent. Results are depicted in Fig 3.

thumbnail
Fig 3. Correlation map of the different molecular imaging parameters in HNSCC.

Correlations between 18F-FDG-PET, T1w-DCE and DWI were computed using Spearman’s non-parametric rank sum correlation coefficient. Numbers in parentheses represent p-values. * p≤ 0.05; ** p≤ 0.01. Bar graphs indicate the distribution of values.

https://doi.org/10.1371/journal.pone.0134749.g003

Discussion

Recently, a study on patients with suspected cancer of the head and neck region undergoing simultaneous 18F-FDG-PET/MRI after routine 18F-FDG-PET/CT was published in which no statistically significant differences regarding sensitivity, specificity, PPV and NPV was found between the two hybrid imaging modalities [1]. The current study demonstrates that the in vivo assessment of glucose metabolism, tissue cell density and microcirculatory parameters of HNSCC is feasible with simultaneous PET/MRI. At this point it has to be acknowledged that these analyses can also be performed on sequentially obtained data. However, this work demonstrates that PET/MRI can display complex interactions between glucose metabolism and microcirculation (expressed by correlations between SUV and Ktrans / kep), between glucose uptake and cellular density (depicted by correlations between SUV and ADC) and between cellularity and volume of the extravascular space (estimated by the correlation between ADC and ve. As all correlations between the different molecular modalities were at best moderate, their combined acquisition seems to provide complementary and not redundant information; yet, they seem to be connected to a certain degree.

We observed a significant correlation and a trend towards a correlation, respectively, between SUVmean/SUVmax and Ktrans. This can be interpreted as an indicator of an elevated neoangiogenesis in tumors with a higher proliferation rate and a higher glucose demand. In these tumors the expression of vascular growth factors might lead to the formation of a primitive vascular plexus. This primitive vascular plexus typically shows an increased leakiness which is represented by the transfer constant Ktrans in the Tofts model [15]. Our results support the theory of other studies in which relations between the vessel permeability measured by T1w-DCE MRI and the expression of vascular endothelial growth factor were observed in colorectal and breast cancer [19,20]. Furthermore, the correlation between glucose metabolism measured by 18F-FDG-PET and vascular endothelial growth factor (VEGF) expression has already been proven for example in oesophageal squamous cell cancer [21]. After leakage into the tumor’s extravascular space, the blood and contrast medium have to be transported back into the plasma, which is expressed by the rate constant kep. As the latter is closely related to Ktrans, also its correlation with glucose uptake seems logical. This also supports a previous study in which a correlation between kep and the FDG dose uptake ratio was reported in patients with breast cancer [22]. For HNSCC Bisdas et al. used CT-perfusion and showed a positive correlation between glucose metabolism and vessel permeability (PS), which is essentially akin to kep [23]. Nevertheless there are ambiguous results described in the literature concerning the relation between glucose metabolism and vessel permeability estimated by kep or Ktrans. In several other studies on HNSCC no correlations between SUVmax and kep and / or Ktrans were detected [8,15]. In a study on hepatocellular carcinomas the authors even reported on an inverse correlation between SUV values and Ktrans [24].

In our study a positive correlation was observed between Ktrans and kep. This positive correlation was also highlighted in a previous examination of patients with HNSCC using T1w-DCE [15]. That study concluded that the enlarged fenestrae of the immature neovessels, which promote contrast medium extravasation (measured by Ktrans) in turn also allow for a fast influx back into the capillary plasma, which is estimated by kep[15]. Moreover, these two parameters are linked by the aforementioned formula kep = Ktrans x ve-1. Another parameter that can be obtained from T1w-DCE analysis is iAUC, the area under the curve. Yet, the interpretation of the correlations for this parameter is difficult and should be treated with caution as iAUC itself is a model-free parameter and is as such prone to variations caused by the length of an acquired T1w-DCE dataset or by different physiological conditions. It was therefore stated by Cheng [25] that conventional iAUC could not be used as a surrogate pharmacokinetic parameter and that pharmacokinetic modelling (e.g. Tofts’ and Kermode’s model [16]) might be the “ideal approach” for accurate quantification—if several conditions, like a valid AIF, are met. This is also why we decided to exclude iAUC from our analysis.

The strong negative correlation between kep and ve supports the results of previous works by Bisdas et al. [15] and Jansen et al. [8] in which similarly strong inverse correlations between these two parameters were observed. The authors ascribed this finding to the smaller interstitial space (expressed by ve) being responsible for a higher back-flux rate into the plasma (represented by kep) because diffusion of a molecule usually happens from a region of higher concentration to one with a lower concentration.

The trend towards a positive correlation between ADCmean and ve that we observed also seems logical. In a tumor with less dense cell complexes the ADC values increase as a measure of less restricted water diffusion; smaller cell density should in turn also result in a larger extravascular space, measured by ve. Yet, this could not be proven in patients with neoplasms of the brain [2628] or the breast [29]. Our results therefore give a hint that this assumption might actually be true, at least with regards to HNSCC.

Concerning the associations between SUVmax and ADCmin we observed a trend towards a weak to moderate inverse correlation in our study. As opposed to the relation between T1w-DCE and DWI and that between T1w-DCE and PET, which have been subject to little research to date, publications about the correlation between 18F-FDG-PET and DWI parameters are numerous and their results partly ambiguous. Since glucose metabolism is known to be positively correlated with the amount of viable tumor cells and growth rate, an inverse correlation between FDG uptake and ADC values, which reflect tumor cellularity, should be expected [7,30]. Nevertheless, whereas this presumption was confirmed for example in rectal [31], cervical [32], lung [33,34] and breast cancer [35], a similar relation could be demonstrated for HNSCC in only one publication [12] whereas in several other studies no such correlation was apparent [3638]. The trend towards a moderate inverse correlation between SUVmax and ADCmin in our patient group might indicate that these parameters are not completely independent and support the hypothesis of Nakajo et al. who concluded that the glycolytic activity of HNSCC seems to be partly related with their microstructural environment [12].

In the future, simultaneous functional imaging with PET/MRI could be of special interest for treatment planning and prognostic stratification of oncologic patients. DWI and T1-DCE as well as 18F-FDG-PET were proven to be suitable for this purpose in patients with HNSCC prior to radiochemotherapy [912]; a satisfactory therapy response and a better prognosis is thought to be related to higher Ktrans [9], higher ADCmean and lower SUVmax values [12]. During successful radiochemotherapy ADC values are increasing [39], whereas 18F-FDG uptake and Ktrans are known to decrease as a sign to therapy response [40,41]. With PET/MRI and a combined acquisition of these parameters further studies to investigate the most suitable modality for assessment and prediction of therapy response are possible.

Our study has several limitations with its small patient number and its retrospective design being the most important ones. The high exclusion rate attributable to technical reasons shows that such sophisticated examinations are probably not yet ready for clinical routine imaging. As it was a pilot study, our results have to be proven for larger patient series. Higher patient numbers could also compensate for the partial lack of statistical significance. As we only studied the tumors themselves and not lymph nodes, on-going studies are focusing on the question to which extent the results are adaptable to nodal metastases in HNSCC.

Conclusion

Simultaneous 18F-FDG-PET/MRI including DWI and T1w-DCE in patients with HNSCC is feasible and allows depiction of complex interactions between glucose metabolism, microcirculatory parameters and cellular density; in the future this might contribute to the planning and adaptation of treatment plans with the aim of optimizing patient outcomes.

Author Contributions

Conceived and designed the experiments: MG SP PS. Performed the experiments: MG SP PS. Analyzed the data: MG. Contributed reagents/materials/analysis tools: TK OS. Wrote the paper: MG PS SP. Critical revision of the manuscript: MG SP KK AB HB RK TK OS PS.

References

  1. 1. Kubiessa K, Purz S, Gawlitza M, Kühn A, Fuchs J, Steinhoff KG, et al. Initial clinical results of simultaneous (18)F-FDG PET/MRI in comparison to (18)F-FDG PET/CT in patients with head and neck cancer. Eur J Nucl Med Mol Imaging. 2013;
  2. 2. Platzek I, Beuthien-Baumann B, Schneider M, Gudziol V, Langner J, Schramm G, et al. PET/MRI in head and neck cancer: initial experience. Eur J Nucl Med Mol Imaging. 2013;40: 6–11. pmid:23053322
  3. 3. Von Schulthess GK, Kuhn FP, Kaufmann P, Veit-Haibach P. Clinical Positron Emission Tomography/Magnetic Resonance Imaging Applications. Semin Nucl Med. 2013;43: 3–10. pmid:23178084
  4. 4. Loeffelbein DJ, Souvatzoglou M, Wankerl V, Martinez-Möller A, Dinges J, Schwaiger M, et al. PET-MRI Fusion in Head-and-Neck Oncology: Current Status and Implications for Hybrid PET/MRI. J Oral Maxillofac Surg. 2012;70: 473–483. pmid:21601338
  5. 5. Sauter AW, Wehrl HF, Kolb A, Judenhofer MS, Pichler BJ. Combined PET/MRI: one step further in multimodality imaging. Trends Mol Med. 2010;16: 508–515. pmid:20851684
  6. 6. Ginat DT, Mangla R, Yeaney G, Johnson M, Ekholm S. Diffusion-weighted imaging for differentiating benign from malignant skull lesions and correlation with cell density. AJR Am J Roentgenol. 2012;198: W597–601. pmid:22623576
  7. 7. Minn H, Clavo AC, Grénman R, Wahl RL. In Vitro Comparison of Cell Proliferation Kinetics and Uptake of Tritiated Fluorodeoxyglucose and L-Methionine in Squamous-Cell Carcinoma of the Head and Neck. J Nucl Med. 1995;36: 252–258. pmid:7830126
  8. 8. Jansen JFA, Schoder H, Lee NY, Stambuk HE, Wang Y, Fury MG, et al. Tumor Metabolism and Perfusion in Head and Neck Squamous Cell Carcinoma: Pretreatment Multimodality Imaging with 1H-Magnetic Resonance Spectroscopy, Dynamic Contrast-Enhanced MRI and 18F-FDG PET. Int J Radiat Oncol Biol Phys. 2012;82: 299–307. pmid:21236594
  9. 9. Kim S, Loevner LA, Quon H, Kilger A, Sherman E, Weinstein G, et al. Prediction of Response to Chemoradiation Therapy in Squamous Cell Carcinomas of the Head and Neck Using Dynamic Contrast-Enhanced MR Imaging. Am J Neuroradiol AJNR. 2010;31: 262–268. pmid:19797785
  10. 10. Ng S-H, Lin C-Y, Chan S-C, Yen T-C, Liao C-T, Chang JT-C, et al. Dynamic contrast-enhanced MR imaging predicts local control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy. PloS One. 2013;8: e72230. pmid:23951300
  11. 11. Berrak S, Chawla S, Kim S, Quon H, Sherman E, Loevner LA, et al. Diffusion weighted imaging in predicting progression free survival in patients with squamous cell carcinomas of the head and neck treated with induction chemotherapy. Acad Radiol. 2011;18: 1225–1232. pmid:21835649
  12. 12. Nakajo M, Nakajo M, Kajiya Y, Tani A, Kamiyama T, Yonekura R, et al. FDG PET/CT and Diffusion-Weighted Imaging of Head and Neck Squamous Cell Carcinoma. Clin Nucl Med. 2012;37: 475–480. pmid:22475897
  13. 13. Sattler B, Jochimsen T, Barthel H, Sommerfeld K, Stumpp P, Hoffmann K-T, et al. Physical and organizational provision for installation, regulatory requirements and implementation of a simultaneous hybrid PET/MR-imaging system in an integrated research and clinical setting. Magma. 2013;26: 159–171. pmid:23053713
  14. 14. Schwenzer NF, Schraml C, Müller M, Brendle C, Sauter A, Spengler W, et al. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging—pilot study. Radiology. 2012;264: 551–558. pmid:22653189
  15. 15. Bisdas S, Seitz O, Middendorp M, Chambron-Pinho N, Bisdas T, Vogl TJ, et al. An exploratory pilot study into the association between microcirculatory parameters derived by MRI-based pharmacokinetic analysis and glucose utilization estimated by PET-CT imaging in head and neck cancer. Eur Radiol. 2010;20: 2358–2366. pmid:20443116
  16. 16. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med. 1991;17: 357–367. pmid:2062210
  17. 17. Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging. 2003;17: 509–520. pmid:12720260
  18. 18. Rosset A, Spadola L, Ratib O. OsiriX: an open-source software for navigating in multidimensional DICOM images. J Digit Imaging. 2004;17: 205–216. pmid:15534753
  19. 19. Knopp M v., Weiss E, Sinn H p., Mattern J, Junkermann H, Radeleff J, et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging. 1999;10: 260–266. pmid:10508285
  20. 20. George ML, Dzik-Jurasz ASK, Padhani AR, Brown G, Tait DM, Eccles SA, et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg. 2001;88: 1628–1636. pmid:11736977
  21. 21. Kobayashi M, Kaida H, Kawahara A, Hattori S, Kurata S, Hayakawa M, et al. The relationship between GLUT-1 and vascular endothelial growth factor expression and 18F-FDG uptake in esophageal squamous cell cancer patients. Clin Nucl Med. 2012;37: 447–452. pmid:22475893
  22. 22. Semple SIK, Gilbert FJ, Redpath TW, Staff RT, Ahearn TS, Welch AE, et al. The relationship between vascular and metabolic characteristics of primary breast tumours. Eur Radiol. 2004;14: 2038–2045. pmid:15316743
  23. 23. Bisdas S, Spicer K, Rumboldt Z. Whole-Tumor Perfusion CT Parameters and Glucose Metabolism Measurements in Head and Neck Squamous Cell Carcinomas: A Pilot Study Using Combined Positron-Emission Tomography/CT Imaging. Am J Neuroradiol AJNR. 2008;29: 1376–1381. pmid:18483187
  24. 24. Ahn SJ, Park M-S, Kim KA, Park JY, Kim I, Kang WJ, et al. 18F-FDG PET metabolic parameters and MRI perfusion and diffusion parameters in hepatocellular carcinoma: a preliminary study. PloS One. 2013;8: e71571. pmid:23940769
  25. 25. Cheng H-LM. Improved correlation to quantitative DCE-MRI pharmacokinetic parameters using a modified initial area under the uptake curve (mIAUC) approach. J Magn Reson Imaging. 2009;30: 864–872. pmid:19787732
  26. 26. Mills SJ, Soh C, Rose CJ, Cheung S, Zhao S, Parker GJM, et al. Candidate Biomarkers of Extravascular Extracellular Space: A Direct Comparison of Apparent Diffusion Coefficient and Dynamic Contrast-Enhanced MR Imaging—Derived Measurement of the Volume of the Extravascular Extracellular Space in Glioblastoma Multiforme. Am J Neuroradiol AJNR. 2010;31: 549–553. pmid:19850765
  27. 27. Chu J-P, Mak HK-F, Yau KK-W, Zhang L, Tsang J, Chan Q, et al. Pilot study on evaluation of any correlation between MR perfusion (Ktrans) and diffusion (apparent diffusion coefficient) parameters in brain tumors at 3 Tesla. Cancer Imaging. 2012;12: 1–6. pmid:22275724
  28. 28. Choi HS, Kim AH, Ahn SS, Shin N, Kim J, Lee S-K. Glioma grading capability: comparisons among parameters from dynamic contrast-enhanced MRI and ADC value on DWI. Korean J Radiol. 2013;14: 487–492. pmid:23690718
  29. 29. Arlinghaus LR, Li X, Rahman AR, Welch EB, Xu L, Gore JC, et al. On the Relationship Between the Apparent Diffusion Coefficient and Extravascular Extracellular Volume Fraction in Human Breast Cancer. Magn Reson Imaging. 2011;29: 630–638. pmid:21531106
  30. 30. Minn H, Lapela M, Klemi PJ, Grénman R, Leskinen S, Lindholm P, et al. Prediction of Survival with Fluorine-18-Fluoro-deoxyglucose and PET in Head and Neck Cancer. J Nucl Med. 1997;38: 1907–1911. pmid:9430467
  31. 31. Gu J, Khong P-L, Wang S, Chan Q, LAW W, Zhang J. Quantitative Assessment of Diffusion-Weighted MR Imaging in Patients with Primary Rectal Cancer: Correlation with FDG-PET/CT. Mol Imaging Biol. 2011;13: 1020–1028. pmid:20872077
  32. 32. Ho K-C, Lin G, Wang J-J, Lai C-H, Chang C-J, Yen T-C. Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer. Eur J Nucl Med Mol Imaging. 2009;36: 200–208. pmid:18779960
  33. 33. Schmidt H, Brendle C, Schraml C, Martirosian P, Bezrukov I, Hetzel J, et al. Correlation of Simultaneously Acquired Diffusion-Weighted Imaging and 2-Deoxy-[18F] fluoro-2-D-glucose Positron Emission Tomography of Pulmonary Lesions in a Dedicated Whole-Body Magnetic Resonance/Positron Emission Tomography System. Invest Radiol. 2013;48: 247–255. pmid:23519008
  34. 34. Regier M, Derlin T, Schwarz D, Laqmani A, Henes FO, Groth M, et al. Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): Does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)? Eur J Radiol. 2012;81: 2913–2918. pmid:22197090
  35. 35. Nakajo M, Kajiya Y, Kaneko T, Kaneko Y, Takasaki T, Tani A, et al. FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion. Eur J Nucl Med Mol Imaging. 2010;37: 2011–2020. pmid:20607535
  36. 36. Choi SH, Paeng JC, Sohn C-H, Pagsisihan JR, Kim Y-J, Kim KG, et al. Correlation of 18F-FDG Uptake with Apparent Diffusion Coefficient Ratio Measured on Standard and High b Value Diffusion MRI in Head and Neck Cancer. J Nucl Med. 2011;52: 1056–1062. pmid:21680692
  37. 37. Fruehwald-Pallamar J, Czerny C, Mayerhoefer ME, Halpern BS, Eder-Czembirek C, Brunner M, et al. Functional imaging in head and neck squamous cell carcinoma: correlation of PET/CT and diffusion-weighted imaging at 3 Tesla. Eur J Nucl Med Mol Imaging. 2011;38: 1009–1019. pmid:21465255
  38. 38. Varoquaux A, Rager O, Lovblad K-O, Masterson K, Dulguerov P, Ratib O, et al. Functional imaging of head and neck squamous cell carcinoma with diffusion-weighted MRI and FDG PET/CT: quantitative analysis of ADC and SUV. Eur J Nucl Med Mol Imaging. 2013;40: 842–852. pmid:23436068
  39. 39. Vandecaveye V, Dirix P, De Keyzer F, Op de Beeck K, Vander Poorten V, Hauben E, et al. Diffusion-weighted magnetic resonance imaging early after chemoradiotherapy to monitor treatment response in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2012;82: 1098–1107. pmid:21514067
  40. 40. Powell C, Schmidt M, Borri M, Koh D-M, Partridge M, Riddell A, et al. Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer. Radiother Oncol. 2013;106: 112–117. pmid:23089306
  41. 41. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med. 2004;45: 56–68. pmid:14734674